Rodman & Renshaw Annual Global Investment Conference
September 11th - 13th, 2016
Lotte New York Palace Hotel, New York City
Rodman & Renshaw will host more than 200 public and private companies at the three-day 18th Annual Global Investment Conference in New York City. This year's conference will connect growth companies together with a vast audience of financial and strategic investors. The more than 2,000 attendees will enjoy access to corporate presentations from growth companies in the healthcare, natural resources, technology, media and telecommunications, cleantech and other industries; investor one-on-one meetings; keynote speakers; and daily networking opportunities over breakfast, lunch and cocktails. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com
Abeona Therapeutics, Inc. (ABEO)
Abeona Therapeutics (NASDAQ: ABEO) is a clinical-stage corporation that focuses on gene therapy and plasma therapy development aimed at rare and lethal genetic diseases. The company identifies key stakeholders interested in promoting breakthrough therapies for rare diseases and puts them in a symbiotic relationship with industry regulators and researchers. The company's main programs include AAV (adeno-associated virus)-based gene treatments for the Sanfilippo syndrome: ABO-101 and ABO-102. Other gene therapy projects aim at finding a cure for other genetic disorders, such as the Fanconi anemia and the juvenile Batten disease by using a gene editing program. For more information, visit the company's website at www.abeonatherapeutics.com.
AcelRx Pharmaceuticals, Inc. (ACRX)
AcelRx Pharmaceuticals (NASDAQ: ACRX) is a specialty pharma company that focuses on the development of innovative treatments for acute pain. Its leading therapies are sufentanil-based and include ARX-04 (30 mcg sublingual tablet) and Zalviso ® (15 mcg sublingual tablet system). Both treatments are designed for the management of moderate-to-severe pain in hospitalized adult patients. The company has reported positive results for ARX-04 from phase 3 studies of the drug's behavior in ambulatory surgery, emergency room and 40+ year-old post-op patients. Additional clinical studies are underway for Zalviso in view of obtaining FDA approval. For more information, visit the company's website at www.acelrx.com.
Actinium Pharmaceuticals, Inc. (ANTM)
Actinium Pharmaceuticals (NYSE: ANTM) is a biopharmaceutical company focused on the development of cancer drugs. The company's product candidates are based on its patented technology, which combines the cancer targeting precision of monoclonal antibodies with the power of alpha emitting radioisotopes, the most potent cancer killing agent in existence. Actinium intends to develop its drug pipeline – which includes Iomab-B for use in hematopoietic stem cell transplantation and Actimab-A for the treatment of acute myeloid leukemia – through phase II clinical trials before partnering each product candidate with an appropriate third party for completion of development and commercialization. For more information, visit the company's website at www.actiniumpharma.com.
Advanced Emissions Solutions, Inc. (ADES)
Advanced Emissions Solutions (NASDAQ: ADES) is a company operating in the field of clean coal technology and the associated specialty chemicals, serving the coal-fueled power plant industry. The company's patented environmental technologies and specialty chemicals enable power plants to enhance their existing air pollution control equipment and improve operating efficiency to meet the challenges of existing and pending emission control regulations. For more information, visit the company's website at www.advancedemissionssolutions.com.
Advaxis, Inc. (ADXS)
Advaxis (ADXS) is a Princeton-based clinical-stage biotechnology corporation that develops cancer immunotherapies based on its unique technology. The company's proprietary patent, Lm Technology™, uses live attenuated Listeria monocytogene bacteria (LM) and is the only immunotherapy agent proven to generate results in preclinical studies. The therapies primarily target HPV-associated cancers and have proven effective on treating phase 2 in neck and head cancer, phase 2 in anal cancer and phase 3 in cervical cancer. The U.S. Food and Drug Administration has granted the company special protocol assessment for treating advance stage cervical cancer (stage 3 and beyond). For more information, visit the company's website at www.advaxis.com.
Aeterna Zentaris, Inc. (AEZS)
Aeterna Zentaris (NASDAQ: AEZS) is a biopharmaceutical company specialized in the development of women's health therapies, ranging from endocrinology to oncology related treatments. Currently engaged in drug developments and the promotion of pharmaceutical products for other companies, Aeterna Zentaris focuses on two main products, Macrilen and Zoptrex, both in phase 3 clinical development in several oncological and endocrinology specialty clinics. Another oncological treatment that is currently in pre-clinical development is called LHRH, a Disorazol Z conjugate (AEZS-138) and is available for partners. For more information, visit the company's website at www.aezsinc.com.
Aethlon Medical, Inc. (AEMD)
Aethlon Medical (NASDAQ: AEMD) is an immunotherapeutic technology developer that uses groundbreaking methods to fight cancer and infectious diseases. The company's patented chief technology is the Aethlon Hemopurifier®, currently under FDA approved clinical study, which functions as an efficient alternative to traditional drug therapies. The technology works by eliminating life threatening disease targets that the body's immune system cannot easily detect. The device is a revolutionary diagnosing and monitoring technology built for capturing bacterial toxins, cancer cells and viruses that are cloaked from immune detection, making early diagnosis and treatment a real possibility. For more information, visit the company's website at www.aethlonmedical.com.
Agenus, Inc. (AGEN)
Agenus (NASDAQ: AGEN) is an immuno-oncology corporation that specializes in discovering groundbreaking new therapies and prevention methods for fighting cancer. Focusing on the body's immune system, the company targets and validates monoclonal antibodies and other immuno-modulatory adjuvants and vaccines that can work in combination with each other to create the best new therapeutic regimens. Prophage™, a heat shock protein-based vaccine developed by Agenus, is currently used in phase 2 trials in treating newly diagnosed glioblastoma. For more information, visit the company's website at www.agenusbio.com.
Akebia Therapeutics, Inc. (AKBA)
Akebia Therapeutics (NASDAQ: AKBA) is a biopharmaceutical company that focuses on the development of new and revolutionary therapies for kidney disease. The company's leading technology is based on HIF (hypoxia- inducible factor) biology. Its main product, Vadasustat, is currently a trial candidate in the treatment of anemia and chronic kidney disease (for both dialysis and non-dialysis patients). The company is going to start the INNO2VATE phase 3 trial program in patients that are dialysis dependent by end of 2016. For more information, visit the company's website at www.akebia.com.
Alliance Healthcare Services, Inc. (AIQ)
Alliance Healthcare Services (NASDAQ: AIQ) is a U.S. provider of outsourced health care services. The company also operates freestanding service clinics in the oncology, radiology and outpatient areas, as well as a few ASC (ambulatory surgical center) units. Alliance is currently the largest provider or stereotactic radiosurgery and an important diagnostic mobile imaging center, operating a network of over 600 fixed-site imaging centers nationwide. Partnering with health systems, hospitals and medical practice throughout the U.S., Alliance currently services over 1,000 hospitals and medical centers in 45 states. For more information, visit the company's website at www.alliancehealthcareservices-us.com.
Alliqua BioMedical, Inc. (ALQA)
Alliqua BioMedical (NASDAQ: ALQA) is a provider of novel care solutions for acute and chronic wounds. Operating both in the U.S. and internationally, the company offers advanced wound care solutions in the following product categories: Human Biologics, Ultrasound Healing Therapy, Antimicrobial Protection, Hydration and Exudate Management. Its commercial wound care portfolio ranges from ultrasound- and saline-based MIST Therapy® to amniotic membrane allograft and various types of contact and hydrogel dressings. Alliqua also manufactures and provides custom electron beam cross-linked hydrogels to the OEM market. For more information, visit the company's website at www.alliqua.com.
Amarin Corp. (AMRN)
Amarin (NASDAQ: AMRN) is a biopharma company focused on the development and marketing of therapies for cardiovascular disease treatment and the overall improvement of cardiovascular function. The Ireland-based company has extensive experience in the study of lipids and the therapeutic effects of polyunsaturated fatty acids, and has leveraged this experience in creating its lead product, Vascepa®, an omega-3 fatty acid capsule available only by prescription. This is Amarin's first FDA-approved product and is used primarily to reduce triglyceride levels in patients with severe hypertriglyceridemia and those with elevated cholesterol levels. For more information, visit the company's website at www.amarincorp.com.
Amedica Corp. (AMDA)
Amedica (NASDAQ: AMDA) develops Silicon Nitride orthopedic and spinal implants. It is the only company that has FDA approval to produce and distribute medical grade Silicon Nitride. Amedica's line of Silicone Nitride Interbody Fusion implants are designed to participate in the fusion process, optimizing patient outcomes. Along with spinal fusion implants, Amediac is developing a corrosion-resistant implant components for dental, hip and knee arthroplasty applications. For more information, visit the company's website at www.amedica.com.
American Superconductor Corp. (AMSC)
American Superconductor (NASDAQ: AMSC) is an energy company focused on developing new technologies and solutions for smarter, cleaner energy. Through its Windtec™ program, the company provides wind turbine electronic controls and systems that reduce the cost of wind energy. As the world's leading producer of 2G HTS wire, AMSC has developed and patented Amperium® for use in all of AMSC's HTS based power products including power cables for its resilient electric grid system, as well as ship protection systems, power generation systems, and electric propulsion systems for the US. Navy. For more information, visit the company's website at www.amsc.com.
AmpliPhi Biosciences Corp. (APHB)
AmpliPhi Biosciences (NYSE: APHB) is a biotech company that focuses on the development of innovative antibacterial therapeutics based on bacteriophage. A global leader in the field, the company has several product candidates that target antibiotic-resistant infections. Its lead product, AB-SA01, is undergoing phase 1 clinical trials for the treatment of staphylococcus aureus infections, while two more products are in development, targeting Pedudomonas aerugiosa lung infections and Clostridium difficile infections. AmpliPhi is working on the new therapies in collaboration with other leading organizations dedicated to bacteriophage-based therapies. For more information, visit the company's website at www.ampliphibio.com.
Amyris, Inc. (AMRS)
Amyris (NASDAQ: AMRS) is an integrated renewable products company enabling the world's foremost brands to achieve sustainable growth. The company applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. Amyris is delivering its proprietary No Compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. For more information, visit the company's website at www.amyris.com.
Anika Therapeutics, Inc. (ANIK)
Anika Therapeutics (NASDAQ: ANIK) is a global orthopedic medicine company that focuses on the development of effective treatments for degenerative or trauma-caused orthopedic conditions. The company's products are based on its proprietary hyaluronic acid (HA) technology, which uses the characteristics of this naturally occurring polymer to maintain the function of healthy joints and tissue. Anika's lead products include Orthovisc® and Monovisc®, which are already being marketed. The company is also exploring other HA applications in fields such as veterinary, dental and ophthalmic care. For more information, visit the company's website at www.anikatherapeutics.com.
Antibe Therapeutics, Inc. (ATBPF)
Antibe Therapeutics (OTC: ATBPF) is a commercial-stage healthcare company focused on the development and sale of highly effective and safe therapies for pain and inflammation, as well as in the area of regenerative medicine. The company's lead product, ATB-346, is designed to address a need for safe, non-addictive medication for chronic pain and inflammation. Other product candidates include a safer analgesic for severe acute pain and an aspirin derivative. Antibe is also targeting the regenerative medicine market through its wholly owned subsidiary, Citagenix, Inc. For more information, visit the company's website at www.antibethera.com.
Apricus Biosciences, Inc. (APRI)
Apricus Biosciences (NASDAQ: APRI) is a biopharmaceutical company that focuses on the advancement of innovative urology and rheumatology therapies. Its staple product, erectile dysfunction treatment Vitaros®, is approved in Canada and Europe and is already being commercialized in several European countries. The company last year in-licensed U.S. development and marketing rights for the drug from Allergan. Apricus is currently developing a second-generation Vitaros that will not require refrigeration, as well as a product candidate for the treatment of Raynaud's disease. For more information, visit the company's website at www.apricusbio.com.
Arch Therapeutics, Inc. (ARTH)
Arch Therapeutics (OTC: ARTH) is a medical device company focused on developing innovative, superior products designed to control leaking and stop bleeding during surgery. The company's products are based on a novel self-assembling peptide technology platform aimed at making surgery safer and faster. Arch Therapeutics' lead product candidate is, AC5 Surgical Hemostatic Device, which is designed to stop bleeding during open surgery and minimally invasive procedures. The product is unique in that it adapts to wound geometry and helps maintain a clear view of the wound area. For more information, visit the company's website at www.archtherapeutics.com.
Asterias Biotherapeutics, Inc. (AST)
Asterias Biotherapeutics (NYSE: AST) is engaged in the emerging field of regenerative medicine. The company's proprietary platforms are based on its pluripotent stem cell and dendritic cell immunotherapy technologies. Asterias' portfolio includes: AST-OPC1, currently in a phase 1/2a dose escalation clinical trial in spinal cord injury; AST-VAC1, which has demonstrated promise in a phase 2 study in acute myelogenous leukemia; and AST-VAC2, which represents a second generation, allogeneic approach to dendritic cell vaccines. For more information, visit the company's website at www.asteriasbiotherapeutics.com.
Atossa Genetics, Inc. (ATOS)
Atossa Genetics (NASDAQ: ATOS) is a clinical-stage pharmaceutical company that focuses on developing innovative delivery methods and therapies for breast cancer and other breast-related conditions. The company's groundbreaking programs use patented intraductal microcatheters that help with the easy delivery of treatments. The company has launched a phase 2 clinical study with the Columbia University Medical Center, delivering Fulvestrant- a potential treatment for DCIS and breast cancer patients - via a breast milk duct delivery device. Atossa Genetics is also developing oral Endoxifen- an alternative to Tamoxifen that is not easily assimilated by breast cancer patients. For more information, visit the company's website at www.atossagenetics.com.
Aurinia Pharmaceuticals, Inc. (AUPH)
Aurinia Pharmaceuticals (NASDAQ: AUPH) is a clinical stage pharmaceutical corporation that focuses on the nephrology field. The company has a clinical trial currently in phase 2 development: AURA-LV, evaluating the performance of its innovative LN (Lupus Nephritis) treatment Volclorsporin. Volclorsporin is a potentially best CNI agent (calcineurin inhibitor) with extensive clinical data in over two thousand affected patients. For more information, visit the company's website at www.auriniapharma.com.
AVEO Pharmaceuticals, Inc. (AVEO)
AVEO Pharmaceuticals (NASDAQ: AVEO) is an advanced biopharmaceutical company promoting a line of targeted therapeutics for oncology. The company's lead clinical candidate is Tivozanib, a selective half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, is promoted as a treatment for several forms of cancer, RCC (Renal Cell Carcinoma) included. The company's aim is to develop and commercialize Tivozanib in non-oncologic indications outside of North America. For more information, visit the company's website at at www.aveooncology.com.
Avino Silver & Gold Mines Ltd. (ASM)
Avino Silver & Gold Mines (NYSE ASM) is a mining and exploration company. Created in 1968, the company's mission is to create shareholder value through profitable organic growth at the historic Avino property near Durango, Mexico, and the Bralorne property in southwestern British Columbia, Canada. Avino Silver is committed to managing all business activities in an environmentally responsible and cost-effective manner while contributing to the well-being of the communities in which it operates. For more information, visit the company's website at www.avino.com.
Aviragen Therapeutics, Inc. (AVIR)
Aviragen Therapeutics (NASDAQ: AVIR), formerly known as Biota Pharma (BOTA), is focused on developing the next generation of direct-acting antivirals aimed at infections with limited treatment options and an increasing number of worldwide patients. The company has three clinical trials in development: Vapendavir- an oral HRV respiratory infection and asthma therapy; BTA585, an oral fusion protein inhibitor which received Fast Track designation by the U.S. FDA; and a topical antiviral therapy for the human papillomavirus types 6 & 11. For more information, visit the company's website at www.aviragentherapeutics.com.
Aytu BioScience, Inc. (AYTU)
Aytu BioScience (OTC: AYTU) is a commercial-stage pharmaceutical company specialized in developing and selling urology therapies. The company currently has three products on the market. ProstaScint® (capromab pendetide) is an imaging agent for prostate specific membrane antigen (PSMA) for prostate cancer detection. Natesto® is the only FDA-approved nasal formulation of testosterone for men with hypogonadism while Primsol® (trimethoprim hydrochloride) is an innovative trimethoprim-only oral solution for urinary tract infections. Aytu is also in development stages with a rapid semen analysis system- MiOXSYS™, aimed at helping management of male infertility. For more information, visit the company's website at www.aytubio.com.
Axsome Therapeutics, Inc. (AXSM)
Axsome Therapeutics (NASDAQ: AXSM) is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for managing disorders of the central nervous system. The company's product candidate portfolio includes two late stage candidates, AXS-02 and AXS-05, currently in clinical testing for multiple indications. Axsome's aim is to become a fully integrated company that develops and sells diverse therapies and treatment options to CNS disorder patients suffering from CNS. For more information, visit the company's website at www.axsome.com.
Ballard Power Systems, Inc. (BLDP)
Ballard Power Systems (NASDAQ: BLDP) is a global provider of innovative clean energy solutions. The company is recognized as a world leader in proton exchange membrane ("PEM") fuel cell development and commercialization. In order to build a clean energy growth company, its business strategy is a two-pronged approach to build shareholder value through the sale and service of power products and the delivery of technology solutions. Ballard uses an Integrated Management System registered to ISO 9001 and ISO 14001 standards, as well as robust internal practices in the areas of automotive core tools, quality, environment, health and safety that conform to the requirements of ISO/TS 16949 and OHSAS 18001. For more information, visit the company's website at www.ballard.com.
Bellerophon Therapeutics, LLC (BLPH)
Bellerophon Therapeutics (NASDAQ: BLPH) is a clinical-stage biotherapeutics company delivering a combination of innovative drugs and delivery devices that address unmet medical needs in the treatment and prevention of cardiopulmonary disease. Under the company's INOpulse proprietary platform (a pulsatile nitric oxide device), there are currently several candidate treatments being assessed one for the treatment of pulmonary arterial hypertension, the others for pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF). For more information, visit the company's website at www.bellerophon.com.
Bio Blast Pharma Ltd. (ORPN)
Bio Blast Pharma (NASDAQ: ORPN) is a clinical-stage biotechnology company that focuses on developing therapies for ultra-rare and potentially incurable genetic diseases. The company's portfolio is built on a deep research and understanding of the processes that cause such diseases and the pathology of each genetic ailment. Bio Blast's lead drug candidate, trehalose 90 mg/mL IV solution, is in clinic development and has reportedly been well-received by the medical community and patients. For more information, visit the company's website: www.bioblastpharma.com.
BioAmber, Inc. (BIOA)
BioAmber (NYSE: BIOA) is a sustainable chemicals company with a proprietary technology platform that combines industrial biotechnology and chemical catalysis to convert renewable feedstock into building block chemicals for use in a wide variety of everyday products including plastics, resins, food additives and personal care products. The company produces bio-based succinic acid by fermenting sugars by using a proprietary yeast strain that has the ability to ferment at a low pH. For more information, visit the company's website at www.bio-amber.com.
BioCancell Ltd. (BCNLF)
BioCancell (OTC: BCNLF) is a clinical-stage biopharma company focused on the discovery and development of innovative therapies for cancer-related diseases. The company is currently undergoing phase 3 clinical studies for its lead product, BC-819, used for the treatment of non-muscle-invasive bladder cancer. The company's BC-821 product is used for advanced malignant neoplasms treatments and has shown promising results during preclinical studies. A third product, BC-830, is being developed as a means to replace expensive, invasive cystoscopies for bladder cancer patients. BioCancell's product candidates rely on a proprietary platform built around the H19 gene present in more than 40 different types of cancer. For more information, visit the company's website at www.biocancell.com.
Biocept, Inc. (BIOC)
Biocept (NASDAQ: BIOC) is a commercial-stage molecular oncology diagnosis company that markets therapies for various forms of cancer such as breast, prostate, lung or melanoma. Using its proprietary liquid biopsy technology, Target Selector™, to provide medical professionals with vital information for monitoring and treating cancer patients, the company's solutions are currently among the most innovative on the market. The patented liquid biopsy technology platform analyzes tumor-associated molecular makers in CTCs (circulating tumor cells) and plasma (ctDNA), identifying cancer mutations and any changes in an efficient manner, allowing treating physicians to identify new therapies for their patients. For more information, visit the company's website at www.biocept.com.
BioDelivery Sciences International, Inc. (BDSI)
BioDelivery Sciences International (NASDAQ: BDSI) is a pharmaceutical company specialized in addiction and pain management medicine. Using a proprietary technology BioErodible MucoAdhesive (BEMA®) as a leading front in the fight against these addictive tendencies, the company aims at creating new applications of proven therapies meant to address current medical needs. BioDelivery Sciences currently works on obtaining more efficient sanction for new formulations of previously approved treatments using the FDA's 505(b)(2) approval process. For more information, visit the company's website at www.bdsi.com.
BioLargo, Inc. (BLGO)
BioLargo (OTC: BLGO) is delivering technology-based products that help solve some of the most widespread problems threatening the world's supply of water, food, agriculture, healthcare and energy. The company showcases the Advanced Oxidation Systems, including its AOS Filter — a product in development specifically designed to eliminate common, troublesome and dangerous contaminants in water in a fraction of the time and cost of current technologies. For more information, visit the company's website at www.biolargo.com.
BioLineRx Ltd. (BLRX)
Israel-based BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company committed to identifying, in-licensing and developing promising therapeutic candidates. The company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization. For more information, visit the company's website at www.biolinerx.com.
Biomerica, Inc. (BMRA)
Biomerica (OTC BB: BMRA) is a global biomedical company that develops and sells advanced diagnostic products used in medical offices for the early detection and monitoring of chronic diseases and medical conditions. The company's medical diagnostic products are focused on two markets: in clinical laboratories and points of care and in drugstores throughout the world. The leading products that Biomerica markets are diagnostic test kits customarily used to analyze blood, urine or fecal specimens from patients in the diagnosis of various diseases, or to measure the level of specific hormones, antibodies, antigens or other substances. For more information, visit the company's website at www.biomerica.com.
Bionomics Ltd. (BNOEF)
Bionomics (OTC: BNOEF) is a global clinical stage biopharmaceutical company focused on developing improved therapies for treating a wide range of diseases ranging from central nervous disorders, depression and anxiety, to cancer and Alzheimer's disease. The company is leveraging its proprietary platform technologies to develop a series of novel drug candidates, such as BNC210, a negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor, currently in phase 2 trials for treating generalized anxiety disorder. Also in clinical stage is BNC101, a lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer, and many other solid tumors. For more information, visit the company's website at www.bionomics.com.au.
Bio-Path Holdings, Inc. (BPTH)
Bio-Path Holdings (NASDAQ: BPTH) is a biotechnology company that focuses on the clinical development of life-saving therapies for cancer and a broad spectrum of indications. The company uses a novel patented method, DNAbilize™, a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification that produces DNA therapeutics for a broad spectrum of diseases. Bio-Path's two lead drug candidates, Liposomal Grb2 (BP1001 and Liposomal Bcl2 (BP1002), are currently in clinical trials for phase 2 acute myeloid leukemia and myeloid leukemia as well as for various breast cancer forms. For more information, visit the company's website at www.biopathholdings.com.
BioSpecifics Technologies Corp. (BSTC)
BioSpecifics Technologies (NASDAQ: BSTC) is a biopharmaceutical company that develops injectable collagenase for 12 clinical indications. The company's proprietary product, injectable collagenase, is marketed as XIAFLEX® in the U.S. and is currently used for the treatment of Dupuytren's contracture and Peyronie's disease. The product is marketed via BioSpecifics' partner, Endo International plc (Endo). XIAFLEX® is also commercialized in Japan, Europe, Canada and Australia for Dupuytren's contracture and also for Peyronie's disease in Europe. Endo is managing the development of XIAFLEX® for frozen shoulder, cellulite, lateral hip fat, plantar fibromatosis and canine lipomas. For more information, visit the company's website at www.biospecifics.com.
Biostage, Inc. (BSTG)
Biostage (NASDAQ: BSTG) is a pioneering biotech corporation focused on regenerative medicine. The company's main goal is to restore organ function of cancer-damaged areas of the human body such as the esophagus, trachea or bronchus. The company uses patented Cellframe™ technology based on over 20 years of scientific progress in the fields of tissue engineering, cell biology and material science. Additionally, the company is creating a new generation of organ implants as a platform capable of being used in the esophagus and main airways (trachea and bronchi). For more information, visit the company's website at www.biostage.com.
BioTime, Inc. (BTX)
BioTime (NYSE: BTX) is clinical-stage biotech that develops and markets innovative therapies in regenerative medicine. The foundation of the company's core therapeutic technology platform is based on various leading stem cell discoveries, but mainly on pluripotent cells that are capable of becoming any of the cell types in the human body. Pluripotent cells have potential application in many areas of medicine such as age-related degenerative diseases and degenerative conditions for which there are no cures in the present. BioTime's research and other activities have resulted in the creation of other subsidiaries that address cancer diagnostics, drug development and cell research products. For more information, visit the company's website at www.biotimeinc.com.
Brainstorm Cell Therapeutics, Inc. (BCLI)
Brainstorm Cell Therapeutics (NASDAQ: BCLI) is an innovative biotechnology company focused on the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of various neurodegenerative diseases. The company commercializes its patented NurOwn® technology through a worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® is in clinical development and has been administered to over 60 patients with ALS in clinical trials conducted in Israel and the United States. The unique technology is also being studied in a randomized, double-blind, placebo-controlled clinical trial at three major clinical centers in the United States. For more information, visit the company's website at www.brainstorm-cell.com.
Brazil Resources, Inc. (BZRSF)
Brazil Resources (OTC: BZRSF) is a mineral exploration company focused on the acquisition and development of gold projects in Brazil and other regions of the Southern Americas. The company is advancing its Cachoeira and São Jorge Gold Projects located in the State of Pará, northeastern Brazil, its Whistler Gold-Copper Project located in the state of Alaska, United States of America, and its Rea Uranium Project in the western Athabasca Basin in northeast Alberta, Canada. For more information, visit the company's website at www.brazilresources.com.
Caladrius Biosciences, Inc. (CLBS)
Caladrius Biosciences (NASDAQ: CLBS) activating through its subsidiary, PCT, is a leading developer and manufacturer of innovative cell therapy treatments and platforms. The company provides a wide range of groundbreaking services, including product and process development, GMP manufacturing, engineering and automation, cell and tissue processing, logistics, storage and distribution. It also provides expert consulting and regulatory support. PCT and its partners collaborate to accelerate the creation of a global commercial cell therapy development. The first stage of this development includes an innovative therapy for Type 1 diabetes based on a proprietary platform technology for immunomodulation. For more information, visit the company's website at www.caladrius.com.
Cancer Genetics, Inc. (CGIX)
Cancer Genetics (NASDAQ: CGIX) operates in the field of personalized medicine, offering precision and best of class diagnostic products and services in the field of oncology. The company's aim is to transform management of cancer and increase therapy efficiency while reducing associated healthcare costs. CGIX is committed to raising standards in clinical treatments by investing in outstanding equipment and technologies. The company's clinical reference laboratory is both CLIA-certified and CAP-accredited, while its clinical trial support services and global facilities help biotech and biopharma companies deliver more personalized treatments to market. For more information, visit the company's website at www.cancergenetics.com.
Can-Fite BioPharma Ltd. (CANF)
Can-Fite BioPharma (NYSE: CANF) is an Israeli biopharmaceutical company with pharmaceutical discovery and clinical development stage capabilities, developing treatments for cancer, inflammatory disease, and sexual dysfunction. The company's CF101 drug candidate is currently under advanced clinical development, preparing to enter phase 3 trials for rheumatoid arthritis and psoriasis. Can-Fite's liver cancer drug CF102 is in phase 2 trials for patients with advanced liver cancer. For more information, visit the company's website at www.can-fite.com.
Capnia, Inc. (CAPN)
Capnia (NASDAQ: CAPN) develops groundbreaking healthcare products focused on detection, screening and treatment of various medical conditions. The company's flagship products are based on its patented technologies, which utilize precision metering of gas flow. A few of the leading products the company markets include Serenz® Allergy Relief; the CoSense® ETCO Monitor measures ETCO, which can be used to detect hemolysis; and the Infant Solutions product line, including innovative pulmonary resuscitation devices for neonates and infants. For more information, visit the company's website at www.capnia.com.
Capstone Turbine Corp. (CPST)
Capstone Turbine (NASDAQ: CPST) is a U.S.-based developer and manufacturer of clean-and-green microturbine power generation systems. The company was the first to market its high efficiency air bearing turbine technology. With over 95 distributors worldwide, Capstone's low-emission microturbines serve multiple vertical markets with industry-leading reliability and efficiency. The company has a comprehensive product lineup, providing scalable solutions from 30kW to 30MW. Capstone microturbines can also operate on a variety of gaseous or liquid fuels and are the ideal solution for today's distributed generation needs. For more information, visit the company's website at www.capstoneturbine.com.
Cardiome Pharma Corp. (CRME)
Cardiome Pharma Corp. (NASDAQ: CRME) is a pharmaceutical company specialized in developing and marketing innovative therapies designed to improve the quality of life and health in patients suffering from heart disease and other afflictions. The company currently has two in-hospital cardiology products: BRINAVESS® (vernakalant IV), used for the conversion of onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT® (tirofiban HCl), a reversible GP IIb/IIIa inhibitor indicated for use in acute coronary syndrome. Cardiome also commercializes a line of short-acting beta-blockers meant to control rapid heart rate in a number of cardiovascular indications: ESMOCARD® and ESMOCARD LYO®. For more information, visit the company's website at www.cardiome.com.
Cascadian Therapeutics, Inc. (CASC)
Cascadian Therapeutics (NASDAQ: CASC) is a clinical-stage biopharmaceutical corporation primarily focused on developing innovative product candidates for the treatment of cancer. The company's main clinical candidate, ONT-380, is an orally active and selective small molecule HER2 inhibitor. The clinical-stage results showed promising systemic activity, a favorable safety profile and encouraging activity against brain metastases. The company is also conducting a randomized, double-blind, placebo-controlled phase 2 study in patients with locally advanced or metastatic breast cancer previously treated with a taxane, trastuzumab, pertuzumab, and T-DM1. For more information, visit the company's website at www.cascadianrx.com.
Catalyst Biosciences, Inc. (CBIO)
Catalyst Biosciences (NASDAQ: CBIO) is a clinical-stage biopharmaceutical company that works on creating and developing innovative therapies for a line of serious medical conditions. The company focuses on the development of therapies in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation. Additional developments include the delayed graft function in renal transplants and the treatment of dry age-related macular degeneration. The company's most advanced program is an improved next-generation coagulation Factor VIIa variant, CB 813d, designed to treat severe hemophilia A and B cases. For more information, visit the company's website at www.catalystbiosciences.com.
Catalyst Pharmaceuticals, Inc. (CPRX)
Catalyst Pharmaceuticals (NASDAQ: CPRX) is a biopharmaceutical company currently developing therapies in the field of rare diseases. The company focuses on congenital diseases such as the Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), infantile spasms, and Tourette's Disorder. Catalyst's revolutionary LEMS treatment, Firdapse, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) and orphan drug designation for LEMS and CMS. The company is also in development phase with a clinically tested product CPP-aimed at treating infantile neurological conditions-spasms, epilepsy. For more information, visit the company's website at www.catalystpharma.com.
Cellectar Biosciences, Inc. (CLRB)
Cellectar Biosciences (NASDAQ: CLRB) is developing agents to detect, treat and monitor a broad spectrum of cancers. With the ability to attach imaging and therapeutic agents to its proprietary delivery platform – a novel phospholipid ether (PLEs) platform technology that is a targeted delivery and retention vehicle, Cellectar has developed a portfolio of product candidates engineered to leverage the unique characteristics of cancer cells to "find, treat and follow" malignancies in a highly selective way. For more information, visit the company's website at www.cellectar.com.
Celsion Corp. (CLSN)
Celsion (NASDAQ: CLSN), a fully integrated oncology company, is focused on developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The company's lead program is ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in phase 3 development for the treatment of primary liver cancer and phase II development for the treatment of recurrent chest wall breast cancer. For more information, visit the company's website at www.celsion.com.
Cemtrex, Inc. (CETX)
Cemtrex (NASDAQ: CETX) is an innovative technology company offering a wide range of products, systems and services to address the needs of a wide variety of industries around the world. The company provides electronic manufacturing services of printed circuit board assemblies, provides instruments for industrial processes as well as industrial environmental control systems. For more information, visit the company's website at www.cemtrex.com.
Cerecor, Inc. (CERC)
Cerecor (NASDAQ: CERC) is a biopharmaceutical company developing new and groundbreaking therapies for neurological and psychiatric disease patients. The company is currently pursuing the development of two clinical phase 2-stage product candidates: CERC-501 and CERC-301, an oral, NR2B-specific, NMDA receptor antagonist. Cerecor is also in clinical phase 2 studies with an MDD adjunctive treatment, CERC-301, and is conducting preclinical tests with CERC-406, a brain penetrant COMT inhibitor with potential pro-cognitive activity. For more information, visit the company's website at www.cerecor.com.
Cesca Therapeutics, Inc. (KOOL)
Cesca Therapeutics (NASDAQ: KOOL) is engaged in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. The company is focused on developing and manufacturing automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. Among others, Cesca's portfolio includes its SurgWerks™ Platform, a proprietary stem cell therapy point-of-care kit systems for treating vascular and orthopedic indications; and CellWerksTM Platform, a proprietary stem cell laboratory kit for processing target cells used in the treatments of oncological and hematological disorders. For more information, visit the company's website at www.cescatherapeutics.com.
Check-Cap Ltd. (CHEK)
Check-Cap (NASDAQ: CHEK) is a clinical-stage medical diagnostics company currently clinically testing the first system for preparation-free scanning and imaging of the inner colon. The company's proprietary system aims to identify precancerous polyps and cancers while being less invasive than traditional procedures. Check-Cap is also developing an ingestible capsule that utilizes exclusive, ultra-low-dose X-ray technology to safely generate high-resolution, 3-dimensional imagery of the interior of the colon. Without requiring bowel preparation or diet and activity modifications, Check-Cap's system is designed to increase patient acceptance and adherence to colorectal cancer screening recommendations. For more information, visit the company's website at www.check-cap.com.
Chembio Diagnostics, Inc. (CEMI)
Chembio Diagnostics (NASDAQ: CEMI) is committed to delivering exceptional products that provide ease of use, and rapid and accurate results at the point-of-care (POC). At the core of its commitment is its patented Next Generation DPP (Dual Path Platform) technology, a breakthrough in POC diagnostics, offering significant advantages over lateral-flow technologies including: significantly improved sensitivity; multiplexing – multiple test results via a single blood sample (e.g., HIV-Syphilis Assay); and application in a number of indications. For more information, visit the company's website at www.chembio.com.
ChromaDex Corp. (CDXC)
ChromaDex (NASDAQ: CDXC) operates a line of complementary business units focused on discovering, acquiring and developing patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The company also focuses on phytochemicals, chemistry and analytical testing services, and product regulatory and safety consulting (known as Spherix Consulting). ChromaDex's patented ingredient technologies include NIAGEN® nicotinamide riboside; pTeroPure® pterostilbene; PURENERGY®, a caffeine-pTeroPure® co-crystal; ProC3G®, a natural black rice containing cyanidin-3-glucoside, IMMULINA™, a spirulina extract; and anthocyanins derived from a domestically produced, water-extracted purple corn. For more information, visit the company's website at www.chromadex.com.
Citius Pharmaceuticals, Inc. (CTXR)
Citius Pharmaceuticals (OTC: CTXR) is a specialty pharmaceutical company that focused on the development and commercialization of critical care products. The company's main focus is on anti-infectives and adjunctive cancer-care drug products using patented or proprietary formulations. Citius is currently advancing two proprietary product candidates, its patented Mino-Lok™ product and a hydrocortisone-lidocaine formulation. For more information, visit the company's website at www.citiuspharma.com.
Codexis, Inc. (CDXS)
Codexis (NASDAQ: CDXS) specializes in providing state-of-the-art enzyme optimization services and developing biocatalyst products. The company's technologies are used to accelerate the development of manufacturing processes for active pharmaceutical ingredients (APIs), fine chemicals, agrochemicals, food ingredients, detergents and biofuels. Codexis' cutting-edge CodeEvolver® is a protein engineering platform that allows rapid development of highly optimized enzymes used in new, highly efficient and environmentally friendly bio catalytic manufacturing processes. For more information, visit the company's website at www.codexis.com.
CombiMatrix Corp. (CBMX)
CombiMatrix (NASDAQ: CBMX) is a clinical, full-scale diagnostic laboratory that specializes in cytogenomic testing for prenatal diagnosis and pediatric developmental disorders. It offers chromosomal microarray analysis, standard and customized FISH, and high resolution karyotyping to help clinicians better care for their patients. CombiMatrix performs genetic testing utilizing a variety of advanced cytogenomic techniques, including next generation sequencing, chromosomal microarray, standardized and customized fluorescence in situ hybridization (FISH) and high-resolution karyotyping. For more information, visit the company's website at www.combimatrix.com.
ContraVir Pharmaceuticals, Inc. (CTRV)
ContraVir Pharmaceuticals (NASDAQ: CTRV) is a biopharmaceutical company that develops and markets targeted antiviral therapies for hepatitis B virus (HBV). The company is developing two novel anti-HBV: CMX157, an analog of the antiviral drug Tenofovir currently in phase 2a, with a potential to reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor. For more information, visit the company's website at www.contravir.com.
COPsync, Inc. (COYN)
COPsync (NASDAQ: COYN) is a U.S.-based technology company that connects law enforcement officers across the nation so they can communicate and share mission-critical information in real-time. This saves officers' lives and keeps the public safer; assists law enforcement officers with catching common criminals and stopping child kidnappings, vehicle thefts, bank robberies and other crimes in progress. The company's technologies also focus on arming law enforcement officers with needed information so they can help defend against terrorism. For more information, visit the company's website at www.copsync.com.
CorMedix, Inc. (CRMD)
CorMedix (NYSE MKT: CRMD) is a biopharmaceutical company that develops and commercializes anti-infective solutions in hemodialysis patients. The company also develops and is in the process of licensing various therapeutic products for the prevention and treatment of infectious and inflammatory diseases. CorMedix's first commercial product is Neutrolin®, a catheter lock solution for the prevention of catheter-related bloodstream infections in hemodialysis or oncology patients. The FDA has granted Fast Track status to Neutrolin as a Qualified Infectious Disease Product for oncology, hemodialysis, and critical care/intensive care patients. For more information, visit the company's website at www.cormedix.com.
CV Sciences, Inc. (CVSI)
CV Sciences (OTC: CVSI) operates on two distinct business segments: developing and marketing CBD (Consumer Cannabidiol) treatments and therapies. The company has a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD. It also manufactures, markets and sells plant-based CBD products to a range of market sectors. Currently distributed nationally in health food stores and health care providers' offices and online, each consumer products brand is backed by a formal safety review, growing body of case reports, and physician's recommendations. For more information, visit the company's website at www.cvsciences.com.
CymBay Therapeutics, Inc. (CBAY)
CymBay Therapeutics (NASDAQ: CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. The company's portfolio includes arhalofenate, which has shown two therapeutic actions in a single drug in multiple phase 2 gout studies; and MBX-8025, a potent, selective, orally active PPARδ agonist. A phase 2 study of MBX-8025 in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay has two ongoing clinical studies for MBX-8025. For more information, visit the company's website at www.cymabay.com.
Cynata Therapeutics Ltd. (CYYNF)
Cynata Therapeutics (OTC: CYYNF) is an Australian medicine company focused on therapeutic stem cell and regenerative technologies. The company's proprietary Cymerus™ platform stem cell technology aims at putting together more efficient treatments for degenerative and serious diseases such as Crohn's, osteoarthritis and heart disease. The technology uses a versatile group of stem cells, MCAs (mesenchymoangioblasts), and employs iPSCs from adult donors as starting material in the manufacturing of the therapeutic solutions. For more information, visit the company's website at www.cynata.com.
CytoDyn, Inc. (CYDY)
CytoDyn (OTC: CYDY) is a biotechnology company that focuses on the clinical development of humanized monoclonal antibodies for HIV treatment and prevention. The company has one of the most important and groundbreaking monoclonal antibodies for HIV infection: PRO 140, which is currently under phase 2 clinical trial and has been proven to block the CCR5 HIV co-receptor. Results on two phase 1 and 2 human trials have shown a significant reduction in the viral burden of infected patients. For more information, visit the company's website at www.cytodyn.com.
Cytori Therapeutics, Inc. (CYTX)
Cytori Therapeutics (NASDAQ: CYTX) is a late stage cell therapy company focused on finding autologous cell therapies from adipose tissue to use for treating several medical conditions. The company's proprietary Cytori Cell Therapy™ mainly acts by improving blood flow, modulating the immune system, and facilitating wound repair. Cytori's herapeutic pipeline is founded upon promising findings in a variety of preclinical and clinical studies, including Cytori-sponsored clinical trials. For more information, visit the company's website at www.cytori.com.
Cytosorbents Corp. (CTSO)
Cytosorbents (NASDAQ: CTSO) is a critical care-focused immunotherapy company using blood purification to control severe inflammation with the goal of preventing or treating multiple organ failure in life-threatening illnesses. CytoSorb®, the company's flagship product, is approved in the EU with distribution in 31 countries around the world, among other uses, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending. For more information, visit the company's website at www.cytosorbents.com.
CytRx Corp. (CYTR)
CytRx (NASDAQ: CYTR) is a biopharmaceutical company focused on the research and development of therapies for various oncology indications. The company's current trials are focused on the development of an improved version of Aldoxorubicin, a best-in-class chemotherapeutic agent, as well as DK049, a novel drug conjugate. CytRx is also planning on expansion of its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx's expertise in albumin biology. For more information, visit the company's website at www.cytrx.com.
DarioHealth Corp. (DRIO)
DarioHealth (NASDAQ: DRIO) provides digital health management solutions that focus on combining and analyzing consumer health data to personalize treatment and advance medical knowledge. The company's main digital product, Dario™ Smart Diabetes Management Solution, is a platform for the management of diabetes. Dario combines an innovative all-in-one blood glucose meter, native smart phone app, website portal, and a wide variety of treatment tools to support more proactive and better informed decisions by users. With marketing clearance in Europe and the U.S., the Dario iOS mobile app is now available in the United Kingdom, Australia, Israel, Italy and Canada. For more information, visit the company's website at www.mydario.investorroom.com.
DBV Technologies S.A. (DBVT)
DBV Technologies S.A. (NASDAQ: DBVT) is a global medical technology company that develops a proprietary technology platform with applications in immunotherapy. Viaskin® is based on epicutaneous immunotherapy, or EPIT®, the company's scientific method of delivering biologically active compounds to the immune system through intact skin. By using this system, DBV is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV Technologies has global headquarters in Montrouge, France, and New York, NY. For more information, visit the company's website at www.dbv-technologies.com.
DelMar Pharmaceuticals, Inc. (DMPI)
DelMar Pharmaceuticals (OTC: DMPI) is a clinical and commercial stage drug development company with a focus on the treatment of cancer. The company is in the midst of conducting clinical trials in the U.S. with its product candidate, VAL-083, which is designed to serve as a potential new treatment for glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. For more information, visit the company's website at www.delmarpharma.com.
Dicerna Pharmaceuticals, Inc. (DRNA)
Dicerna Pharmaceuticals (NASDAQ: DRNA) is an RNA interference-based biopharmaceutical company focused on developing innovative treatments for rare, inherited diseases. Most of the attributions under research involve diseases of the liver, other therapeutic areas in which the liver plays a key role, and cancers that are genetically defined. By using its proprietary RNA interference (RNAi) technology platform the company is pursuing targets that have historically been difficult to inhibit using conventional approaches. For more information, visit the company's website at www.dicerna.com.
Diffusion Pharmaceuticals, Inc. (DFFN)
Diffusion Pharmaceuticals (OTC: DFFN) is a clinical stage biotech corporation focused on extending the life expectancy of cancer patients. The company is developing its lead drug, trans sodium crocetinate (TSC), to be used in many cancer types in which tumor hypoxia (oxygen deprivation) affects the effectiveness of current treatments. TSC targets the cancer's hypoxic micro-environment. A phase 2 clinical program, completed in 2015, evaluated 59 patients with newly diagnosed glioblastoma multiforme (GBM) and proved a favorable safety and efficacy profile for TSC combined with standard of care. For more information, visit the company's website at www.diffusionpharma.com.
Dipexium Pharmaceuticals, Inc. (DPRX)
Dipexium Pharmaceuticals (NASDAQ: DPRX) is a late stage pharmaceutical company focused on developing and selling Locilex (pexiganan cream 0.8%), a potent and broad spectrum topical antibiotic peptide, for the treatment of mild and moderate skin and skin structure infections. The company means to establish Locilex as the standard of care for the treatment of mild infections of diabetic foot ulcers, an indication for which there are currently no products specifically approved by the U.S. Food and Drug Administration. For more information, visit the company's website at www.dipexiumpharmaceuticals.com.
DragonWave, Inc. (DRWI)
DragonWave (NASDAQ: DRWI) is a Canadian provider of high-capacity microwave solutions that drive next-generation IP networks. The company's carrier-grade point-to-point packet microwave systems enable service providers, government agencies, enterprises, and other organizations to meet their increasing bandwidth requirements. DragonWave's portfolio includes a wireless network backhaul solution, including a range of products ideally suited to support the emergence of underlying small cell networks. For more information, visit the company's website at www.dragonwaveinc.com.
DRDGOLD Ltd. (DRD)
DRDGOLD (NYSE: DRD) is a South African gold producer and a specialist in the recovery of the metal from the retreatment of surface tailings. With a long corporate history, the company is developing and refining a strategy of deploying their resources, to mine not only profitably, but also optimally, ensuring that the business remains sustainable well into the 21st Century. For more information, visit the company's website at www.drd.co.za.
DURECT Corp. (DRRX)
DURECT (NASDAQ: DRRX) is a biopharmaceutical company focused on developing new therapeutics based on its proprietary drug delivery platforms and new chemical entities derived from its Epigenomic Regulator Program. The company's proprietary systems are being applied chiefly to the fields of acute organ injury and metabolic diseases such as NAFLD/NASH, pain management, CNS disorders. Late-stage development programs include POSIMIR® (SABER®-Bupivacaine) and REMOXY® (ORADUR®-oxycodone). For more information, visit the company's website at www.durect.com.
EDAP TMS SA (EDAP)
EDAP TMS SA (NASDAQ: EDAP) is a veteran biopharmaceutical company founded in 1979, highly committed to developing new and innovative technologies for a minimally invasive approach to treating urological disorders. The company's proprietary technologies have yielded new minimally invasive procedures for the treatment of several pathologies such as benign prostatic hyperplasia, localized prostate cancer, or urinary tract stones. The EDAP TMS products are alternatives to traditional surgical procedures which often involve high costs, significant side effects, and long recovery times. For more information, visit the company's website at www.edap-tms.com.
Endeavour Silver Corp. (EXK)
Endeavour Silver (NYSE: EXK) is a mid-tier precious metals mining company that owns three high grade, underground, silver-gold mines in Mexico. Since 2004 the company has grown from no production to 11.4 million ounces of silver equivalent production in 2015. It finds, builds and operates quality silver mines in a socially, economically and environmentally responsible manner to create real value for all stakeholders. For more information, visit the company's website at www.edrsilver.com.
Energy Focus, Inc. (EFOI)
Energy Focus (NASDAQ: EFOI) provides energy efficient LED lighting products, and is a developer of energy efficient lighting technology. The company's solutions provide energy savings, aesthetics, safety and maintenance cost benefits over conventional lighting. Its long-running collaboration with the U.S. Government includes numerous research and development projects for the DOE and DARPA, creating energy efficient LED lighting systems for the U.S. Navy fleet. Customers include national, state and local U.S. government agencies as well as Fortune 500 companies, the U.S. Navy and many others. For more information, visit the company's website at www.energyfocusinc.com.
Energy Fuels, Inc. (UUUU)
Energy Fuels (NYSE: UUUU) is a U.S.-based, integrated producer of uranium. The company utilizes both conventional and in-situ recovery ("ISR") technology and produces uranium from two strategic facilities – the White Mesa Mill in Utah (conventional) and the Nichols Ranch Plant in Wyoming (ISR). Energy Fuels' portfolio boasts a book of premium-priced sales contracts with major nuclear utilities, an industry-leading U.S.-based NI 43-101 Mineral Resource portfolio among producers, and a pipeline of high-quality, large-scale development and exploration projects. For more information, visit the company's website at www.energyfuels.com.
EnSync, Inc. (ESNC)
EnSync (NYSE: ESNC) is a company dedicated to enabling the future of electricity through advanced energy management systems critical to a global economy that is becoming increasingly reliant upon the expansion of renewable energy. Whether part of the grid power transmission and distribution network, or behind the meter in commercial, industrial and multi-tenant buildings, the company's technology brings differentiated power control and energy storage solutions to electricity-challenged environments. For more information, visit the company's website at www.ensync.com.
Enzo Biochem, Inc. (ENZ)
Enzo Biochem (NYSE: ENZ) is a life sciences and biotechnology company that harnesses genetic processes to develop research tools, diagnostics and therapeutics. The company has made it its mission to develop enabling technologies in the areas of gene regulation and gene modification. Many of their technologies are applicable to the biomedical and pharmaceutical research markets, and are used further as platforms for entering the clinical diagnostics market. The research and development activities are currently performed by the company's three subsidiaries: Enzo Life Sciences, Enzo Therapeutics and Enzo Clinical Labs. For more information, visit the company's website at www.enzo.com.
Epizyme, Inc. (EPZM)
Epizyme (NASDAQ: EPZM) is a clinical stage biopharmaceutical company focused on developing innovative epigenetic therapies for patients with cancer. The company's vision is to rewrite cancer therapy and change the standard of care for patients and physicians by developing medicines with fundamentally new mechanisms of action. The company's proprietary creation, Tazemetostat, has demonstrated the potential to treat both hematologic malignancies and solid tumors, which laid the foundation for its aggressive development plan. For more information, visit the company's website at www.epizyme.com.
ESSA Pharma, Inc. (EPIX)
ESSA Pharma (NASDAQ: EPIX) is focused on the development of small molecule drugs for the treatment of cancer, with a focus on advanced prostate cancer. The company is currently developing drugs that selectively block the N-terminal domain of the androgen receptor (AR). The AR is required for the growth and survival of most prostate cancer; therefore, the AR N-terminal domain is an ideal target for next-generation hormone therapy. In 2014, ESSA was awarded a grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to support the clinical development program of EPI compounds. For more information, visit the company's website at www.essapharma.com.
Evogene Ltd. (EVGN)
Evogene (OTC: EVGN) is an Israel-based company focused on plant genomics. It utilizes a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. The company provides a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure. Evogene has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. For more information, visit the company's website at www.evogene.com.
Evoke Pharma, Inc. (EVOK)
Evoke Pharma (NASDAQ: EVOK) is a pharmaceutical company specialized mainly in the development of drugs to treat gastrointestinal (GI) diseases. The company's lead product candidate, EVK-001, is in late stage clinical testing. Evoke Pharma has exclusive rights to a novel formulation and delivery of a currently marketed GI product. The product is intended for the treatment of diabetic gastroparesis. For more information, visit the company's website at www.evokepharma.com.
Evolution Petroleum Corp. (EPM)
Evolution Petroleum (NYSE: EPM) is a leading U.S.-based company that develops incremental petroleum reserves and shareholder value by applying conventional and specialized technology to known oil and gas resources, onshore. Principal assets include interests in a CO2-EOR project in Louisiana's Delhi Field and a patented technology designed to extend the life and increase ultimate recoveries of depletion drive oil and gas wells. For more information, visit the company's website at www.evolutionpetroleum.com.
EVOLVA Holding (ELVAY)
EVOLVA Holding (OTC: ELVAY) is a global company focused on sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. The company's products include Stevia, Resveratrol, Vanillin, Nootkatone and Saffron. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information, visit the company's website at www.evolva.com.
Exactus, Inc. (EXDI)
Exactus (OTC: EXDI) is a life science company that is developing and commercializing Point-of-Care (POC) diagnostics for measuring proteolytic enzymes in the blood based on a detection platform. The company's primary business focus is the development and commercialization of the FibriLyzer, a disposable test biosensor strip combined with a portable hand held detection unit that provides a result in approximately 30 seconds. For more information, visit the company's website at www.exactus.net.
Exeter Resource Corp. (XRA)
Exeter Resource (NYSE: XRA) is a mineral exploration company engaged in the acquisition, exploration and development of resource properties in the Americas. The company is dedicated to the exploration and development of the Caspiche copper gold porphyry project in the Maricunga District in Chile. Corporate operations are directed from Vancouver and Chile. For more information, visit the company's website at www.exeterresource.com.
Eyegate Pharmaceuticals, Inc. (EYEG)
Eyegate Pharmaceuticals (NASDAQ: EYEG) is a clinical-stage pharmaceutical developing products for treating diseases and disorders of the eye. The company's product in clinical trials, EGP-437, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate, that is delivered into the ocular tissues through EyeGate's proprietary technology, the EyeGate® II Delivery System. In addition, EyeGate is developing products using cross-linked thiolated carboxymethyl hyaluronic acid ("CMHA-S"), a modified form of the natural polymer hyaluronic acid (HA) with extraordinary hydration and healing properties. For more information, visit the company's website at www.eyegatepharma.com.
Fate Therapeutics, Inc. (FATE)
Fate Therapeutics (NASDAQ: FATE) is a clinical‑stage biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life‑threatening diseases. The company is primarily focused on developing programmed hematopoietic cellular candidates as therapeutic entities for the treatment of hematologic malignancies, rare genetic disorders, and diseases resulting from the dysregulation of the immune system. Fate has built a novel platform to program the function and fate of cells ex vivo using pharmacologic modulators, such as small molecules. For more information, visit the company's website at www.fatetherapeutics.com.
Fennec Pharmaceuticals, Inc. (FENCF)
Fennec Pharmaceuticals (OTC: FENCF) is a clinical-stage biotechnology company developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. STS is being investigated in two pediatric phase 3 studies to evaluate the reduction of ototoxicity and impact on survival of pediatric patients. For more information, visit the company's website at www.fennecpharma.com.
Finjan Holdings, Inc. (FNJN)
Finjan Holdings (NASDAQ: FNJN) is a globally recognized leader in cybersecurity with 20 years of activity in the field. The company's inventions are embedded within a strong portfolio of patents focusing on software and hardware technologies capable of proactively detecting previously unknown and emerging threats on a real-time, behavior-based basis. Finjan continues to grow through investments in innovation, strategic acquisitions, and partnerships promoting economic advancement and job creation. For more information, visit the company's website at www.finjan.com.
First Majestic Silver Corp. (AG)
First Majestic Silver (NYSE: AG) is a mining company focused on silver production in Mexico. The company is aggressively pursuing the development of its existing mineral property assets and presently owns and operates six producing silver mines: the La Parrilla Silver Mine, the San Martin Silver Mine, the La Encantada Silver Mine, the La Guitarra Silver Mine, Del Toro Silver Mine and the Santa Elena Silver Mine. Production from these six mines is anticipated to be between 10.7 to 11.9 million ounces of pure silver or 16.8 to 18.7 million ounces of silver equivalents in 2016. For more information, visit the company's website at www.firstmajestic.com.
First Mining Finance Corp. (FFMGF)
First Mining Finance (OTC: FFMGF) is a mineral property holding company dedicated to acquiring and holding high-quality mineral assets with a focus in the Americas. The company currently holds a portfolio of 28 mineral assets in Canada, Mexico, and the United States with a focus on gold. Ultimately, the goal is to continue to increase its portfolio of mineral assets through acquisitions that are expected to be comprised of gold, silver, copper, lead, zinc and nickel. For more information, visit the company's website at www.firstminingfinance.com.
Fission Uranium Corp. (FCUUF)
Fission Uranium (OTC: FCUUF) is a Canadian-based resource company specializing in the strategic exploration and development of the Patterson Lake South uranium property - host to the world-class Triple R uranium deposit - and is headquartered in Kelowna, British Columbia. Exploration is ongoing at the PLS uranium discovery, which continues to develop as a high-grade, shallow depth uranium deposit. For more information, visit the company's website at www.fissionuranium.com.
Flex Pharma, Inc. (FLKS)
Flex Pharma (NASDAQ: FLKS) is a biotechnology company developing innovative and proprietary therapies for nocturnal leg cramps, and cramps and spasms associated with severe neuromuscular conditions such as MS and ALS, and exercise-associated muscle cramps. The company was founded by National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., both of which are recognized leaders in the fields of ion channels and neurobiology, along with chair and CEO Christoph Westphal, M.D., Ph.D. For more information, visit the company's website at www.flex-pharma.com.
Foamix Pharmaceuticals Ltd. (FOMX)
Foamix Pharmaceuticals (NASDAQ: FOMX) is a specialty pharmaceutical company that develops and markets innovative and differentiated topical drugs for dermatological therapy. The company's clinical stage product candidates include FMX101, a novel minocycline foam for the treatment of moderate-to-severe acne; FMX102 for the treatment of impetigo; FMX 103 for the treatment of rosacea; and FDX104, a doxycycline foam for the management of acne-like rash, induced by EGFRI anticancer drugs. For more information, visit the company's website at www.foamixpharma.com.
FTE Networks, Inc. (FTNW)
FTE Networks (OTC: FTNW) is an international networking infrastructure solutions company that designs, builds and supports telecommunications and technology systems and infrastructure services for companies through four industry segments: data center infrastructure, fiber optics, wireless integration, and surveillance & security. FTE Networks is based in Naples, Florida, with subsidiaries throughout the United States and Europe. For more information, visit the company's website at www.ftenet.com.
Galectin Therapeutics, Inc. (GALT)
Galectin Therapeutics (NASDAQ: GALT) is a clinical-stage company developing therapies for the treatment of fibrotic liver disease and cancer. The therapies are based on the company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin Therapeutics is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis, psoriasis and cancer. For more information, visit the company's website at www.galectintherapeutics.com.
Galena Biopharma, Inc. (GALE)
Galena Biopharma (NASDAQ: GALE) is a biopharmaceutical company that develops and markets hematology and oncology therapeutics that address unmet medical needs. The company's development portfolio is focused on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. Galena's pipeline consists of multiple mid-to-late-stage clinical assets led by its hematology asset, GALE-401, along with its novel cancer immunotherapy programs including NeuVax™ (nelipepimut-S) and GALE-301/GALE-302. For more information, visit the company's website at www.galenabiopharma.com.
Galmed Pharmaceuticals Ltd. (GLMD)
Galmed Pharmaceuticals (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company developing innovative once-daily, oral therapy for the treatment of liver diseases. The company utilizes its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Galmed is currently conducting the ARREST Study, a multicenter, randomized, double blind, placebo-controlled phase 2b clinical study designed to evaluate the efficacy and safety of Aramchol™ in subjects with NASH, who are overweight or obese, and who are pre-diabetic or type-II-diabetic. For more information, visit the company's website at www.galmedpharma.com.
General Moly, Inc. (GMO)
General Moly (NYSE: GMO) is a U.S.-based mineral company focused on the exploration, development and mining of molybdenum ("moly"). The company owns two world-class moly projects: an 80% interest in the Mt. Hope project and 100% of the Liberty project. Both are located in Nevada, U.S.A. For more information, visit the company's website at www.generalmoly.com.
Gevo, Inc. (GEVO)
Gevo (NASDAQ: GEVO) is a renewable chemicals and advanced biofuels company that has developed bio-based alternatives to petroleum-based products using a combination of synthetic biology and chemistry. Gevo currently produces isobutanol, a multipurpose platform chemical for the liquid fuels and petrochemical market with broad market applications as a solvent and a gasoline blend stock that can help refiners meet their renewable fuel and clean air obligations. It can also be further processed using well-known chemical processes into jet fuel and feedstocks for the production of synthetic rubber, plastics, and polyesters. For more information, visit the company's website at www.gevo.com.
Gilat Satellite Networks Ltd. (GILT)
Gilat Satellite Networks (NASDAQ: GILT) provides end-to-end satellite-based broadband communication solutions. The company specializes in fixed and on-the-move communications for commercial and government entities. Its offerings are specifically tuned to take advantage of high throughput satellites (HTS) as well as wide beam satellites. Gillat Satellite develops groundbreaking technology in five R&D centers to support a wide range of high-performance satellite ground segment VSAT equipment, and small-cells for an integrated cellular offering. For more information, visit the company's website at www.gilat.com.
GoGold Resources, Inc. (GLGDF)
GoGold Resources (OTC: GLGDF) is a Canadian-based silver and gold producer focused on operating, developing, exploring and acquiring high quality projects in Mexico. The company's Parral Tailings project is one of the lowest cash cost silver producers in the world. GoGold is building a portfolio of low cost, high margin projects. For more information, visit the company's website at www.gogoldresources.com.
Golden Minerals Company (AUMN)
Golden Minerals (NYSE: AUMN) is a precious metals mining company focused on South America. The company owns the Velardeña Properties and associated oxide and sulfide processing plants in the State of Durango, Mexico; the El Quevar advanced exploration property in the province of Salta, Argentina; and a diversified portfolio of precious metals and other mineral exploration properties located primarily in or near historical precious metals producing regions of Mexico. For more information, visit the company's website at www.goldenminerals.com.
Golden Queen Mining Co. Ltd. (GQMNF)
Golden Queen Mining (OTC: GQMNF) is a precious metals mining company currently producing gold and silver at the Soledad Mountain Project located just outside the town of Mojave in California. The company project is utilizing conventional open pit mining methods and cyanide heap leach and Merrill-Crowe processes to recover gold and silver from crushed, agglomerated ore. Annual gold and silver production is projected to average approximately 74k oz and 781k oz, respectively, although this is expected to fluctuate from year to year depending upon the ore head grades. For more information, visit the company's website at www.goldenqueen.com.
Great Panther Silver Ltd. (GPL)
Great Panther Silver (NYSE: GPL) is a precious metals mining and exploration company mainly focused on silver extraction. Great Panther's current activities are focused on the mining of precious metals from its two wholly owned operating mines in Mexico: the Guanajuato Mine Complex, which includes the San Ignacio Mine, and the Topia Mine in Durango. For more information, visit the company's website at www.greatpanther.com.
Hansa Medical AB (HNSBF)
Hansa Medical AB (OTC: HNSBF) is a biopharmaceutical company focusing on novel immunomodulatory enzymes. The company's lead project, IdeS, is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Additional projects focus on development of new antibody modulating enzymes, as well as HBP, a diagnostic biomarker for prediction of severe sepsis at emergency departments that is already introduced on the market. The company is based in Lund, Sweden. For more information, visit the company's website at www.hansamedical.com.
Hecla Mining Company (HL)
Hecla Mining (NYSE: HL) is a veteran U.S. mining company. Founded in 1891, the company is a leading low-cost U.S. silver producer with operating mines in Alaska, Idaho and Mexico, and is a growing gold producer with an operating mine in Quebec, Canada. It also has exploration and pre-development properties in six world-class silver and gold mining districts in the U.S., Canada and Mexico, and an exploration office and investments in early-stage silver exploration projects in Canada. For more information, visit the company's website at www.hecla-mining.com.
HedgePath Pharmaceuticals, Inc. (HPPI)
HedgePath Pharmaceuticals (OTC: HPPI) is a clinical-stage biopharmaceutical company that develops groundbreaking therapeutics for patients with cancer. The company is also exploring options to acquire or license innovative therapeutics that address unmet needs and orphan indications beyond cancer. HedgePath is focused on the development of therapies for more than one type of cancer, with initial emphasis in the U.S. market, based upon repurposing the currently marketed antifungal drug itraconazole for new indications in oncology. For more information, visit the company's website at www.hedgepathpharma.com.
Hemispherx Biopharma, Inc. (HEB)
Hemispherx Biopharma (NYSE: HEB) is a pharmaceutical company specialized in the clinical development of new drugs for the treatment of seriously debilitating disorders of the immune system. The company's flagship products are the experimental therapeutics Ampligen®, an experimental RNA nucleic acid being developed for the Chronic Fatigue Syndrome and other globally important debilitating diseases; Alferon® LDO; and Alferon N Injection®. The FDA approval of Alferon N Injection® is limited to the treatment of refractory or recurrent external genital warts. For more information, visit the company's website at www.hemispherx.net.
Histogenics Corp. (HSGX)
Histogenics (HSGX) is focused on developing and commercializing products in the regenerative musculoskeletal market. The company's regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bio adhesives, and growth factors to deliver high-quality solutions for musculoskeletal-related conditions. Its first investigational product candidate, NeoCart®, will provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee. For more information, visit the company's website at www.histogenics.com.
Hydrogenics Corp. (HYGS)
Hydrogenics (NASDAQ: HYGS) is a global leader in the designing, manufacturing, building and installing industrial and commercial hydrogen systems. With 60 years of experience, the company provides leading expertise for a range of applications: hydrogen generators for industrial processes and fueling stations, hydrogen fuel cells for electric vehicles such as urban transit buses, commercial fleets, utility vehicles and electric lift trucks. Hydrogenics is currently pioneering "Power-to-Gas" the world's most innovative way to store and transport energy. The company is based in Mississauga, Canada, with manufacturing facilities located in Germany and Belgium. For more information, visit the company's website at www.hydrogenics.com.
Ideal Power, Inc. (IPWR)
Ideal Power (NASDAQ: IPWR) is an innovative technology company dedicated to advancing the efficiency of electric power conversion. The company has developed a patented power conversion technology called Power Packet Switching Architecture™ ("PPSA"), which improves the efficiency and reliability of electronic power converters. It has also developed and patented a bi-directional, bi-polar junction transistor ("B-TRAN™") which has the potential to dramatically increase bi-directional power switching efficiency and energy density. For more information, visit the company's website at www.utilitydive.com.
Immunomedics, Inc. (IMMU)
Immunomedics (NASDAQ: IMMU) is a clinical-stage biopharmaceutical corporation that focuses on the development of monoclonal antibody-based therapies for cancer and autoimmune disorders. The company's proprietary technologies allow the creation of humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Immunomedics has eight clinical-stage product candidates. The most advanced are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in phase 2 trials for treating solid tumors and metastatic colorectal cancer. IMMU-132 has received Breakthrough Therapy Designation from FDA for the treatment of patients with triple-negative breast cancer. For more information, visit the company's website at www.immunomedics.com.
ImmunoVaccine Inc. (IMMVF)
ImmunoVaccine Inc. (OTC: IMMVF) is a biopharmaceutical company developing groundbreaking cancer immunotherapies and infectious disease vaccines based on its proprietary platform. The company's DepoVax™ platform is a patented formulation that provides prolonged exposure of antigens and adjuvants to the immune system. ImmunoVaccine has advanced two T cell activation therapies for cancer through phase 1 human clinical trials and is presently in a phase 2 study with its lead cancer vaccine therapy, DPX-Survivac, aimed at recurrent lymphoma. For more information, visit the company's website at www.imvaccine.com.
Innoviva, Inc. (INVA)
Innoviva (NASDAQ: INVA), formerly known as Theravance, Inc., is a biopharmaceutical company that focuses on producing compelling new remedies for respiratory diseases. The company's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Under the agreement with Glaxo Group, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®. For more information, visit the company's website at www.inva.com.
Innovus Pharmaceuticals, Inc. (INNV)
Innovus Pharmaceuticals (OTC: INNV) provides over-the-counter and consumer products for men's and women's health and vitality. The company currently markets its four lead products: BTH® Testosterone Booster; BTH® Human Growth Agent; Zestra® for female arousal; and EjectDelay® for premature ejaculation. Innovus also has five marketed products in this space, including Sensum+® for the indication of reduced penile sensitivity; Zestra Glide®; Vesele® for promoting sexual and cognitive health; Androferti® to support overall male reproductive health and sperm quality; and BTH Vision Formula. For more information, visit the company's website at www.innovuspharma.com.
Inotek Pharmaceuticals Corp. (ITEK)
Inotek Pharmaceuticals (NASDAQ: ITEK) is a clinical-stage biopharmaceutical company that works on the development of innovative therapies for glaucoma and other serious diseases of the eye. The company's lead product candidate, Trabodenoson, is a first-in-class selective adenosine mimetic developed to selectively stimulate the adenosine subreceptor, which has completed phase 2 in clinical development for treatments of primary open-angle glaucoma (POAG) and ocular hypertensive (OHT). For more information, visit the company's website at www.inotekpharma.com.
Inovio Pharmaceuticals, Inc. (INO)
Inovio Pharmaceuticals (NASDAQ: INO) is on a quest to expand immune system stimulation to revolutionize the fight against cancers and infectious diseases. Stimulating the body's immune system remains one of the most promising approaches to addressing the unmet needs of cancers, HIV, hepatitis, and other diseases, and the company's DNA-based immunotherapy technology platform is progressively showing its potential to establish a new paradigm to prevent and treat life-altering diseases, with validating efficacy data from a large controlled phase 2 study. For more information, visit the company's website at www.inovio.com.
Intec Pharma Ltd. (NTEC)
Intec Pharma (NASDAQ: NTEC) is developing drugs based on its proprietary Accordion Pill platform technology. Accordion Pill is an oral drug delivery system designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The company's product pipeline currently includes three product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa (AP-CDLD) for the indication of treatment of Parkinson's disease symptoms; Accordion Pill Zaleplon (AP-ZP) for treatment of insomnia; and a third Accordion Pill for the treatment of gastoduodenal and small bowel NSAID-induced ulcers. For more information, visit the company's website at www.intecpharma.com.
IntelGenx Technologies Corp. (IGXT)
IntelGenx Technologies (OTC: IGXT) is an oral drug delivery company focused on the development and manufacturing of innovative pharmaceutical oral films using the company's proprietary VersaFilm™ technology platform. The company provides leading services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the art manufacturing facility, established for the VersaFilm technology platform, supports lab-scale to pilot and commercial-scale production. For more information, visit the company's website at www.intelgenx.com.
Intellipharmaceutics International, Inc. (IPCI)
Intellipharmaceutics International (NASDAQ: IPCI) is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Controlled-release means releasing a drug into the bloodstream or at a target site in the body, over an extended period of time. This type of delivery can enhance efficacy and patient compliance as compared to immediate release formats for the same drug. Hypermatrix technology is the company's propriety product and allows for the intelligent and efficient design of drugs through the precise control of several key variables including varying drug attributes and patient requirements. For more information, visit the company's website at www.intellipharmaceutics.com.
Interleukin Genetics, Inc. (ILIU)
Interleukin Genetics (OTC: ILIU) is a research company that develops proprietary genetic tests for chronic inflammatory diseases and health-related conditions. The company's lead products include its proprietary PerioPredict® genetic test which identifies individuals at risk for severe periodontal disease and a life-long predisposition to overproduce inflammation, and its Inherent Health® line of genetic tests. For more information, visit the company website at www.ilgenetics.com.
Intermolecular, Inc. (IMI)
Intermolecular (NASDAQ: IMI) is a technology company focused on advanced materials innovation. Advanced materials are at the core of innovation for a wide range of industries, including semiconductors, consumer electronics, automotive and aerospace. With substantial materials expertise, an accelerated learning and experimentation platform, and information and analytics infrastructure, the company has a 10-year track record helping leading companies accelerate and de-risk materials innovation. For more information, visit the company's website at www.intermolecular.com.
International Stem Cell Corp. (ISCO)
International Stem Cell (OTC: ISCO) is a pharmaceutical company focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs). The company's scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. For more information, visit the company's website at www.internationalstemcell.com.
Inventergy Global, Inc. (INVT)
Inventergy Global (NASDAQ: INVT) is an intellectual property company dedicated to identifying, acquiring and licensing patented technologies of market-significant technology leaders. Led by IP industry pioneer and veteran Joe Beyers, the Silicon Valley-based company leverages decades of corporate experience, market and technology expertise, and industry connections to assist Fortune 500 and other technology companies in leveraging the value of their innovations to achieve greater returns. For more information, visit the company's website at www.inventergy.com.
InVivo Therapeutics Holdings Corp. (NVIV)
InVivo Therapeutics Holdings (NASDAQ: NVIV) is on a quest to redefine the life of the spinal cord injury patient. Armed with cutting-edge technology and MIT science, experienced business and medical professionals at InVivo Therapeutics are pushing the boundaries of spinal cord injury research. As the recognized leader in the SCI field, the company has a singular focus: improving quality-of-life — and redefining life — for the SCI patients it serves. For more information, visit the company's website at www.invivotherapeutics.com.
IsoRay, Inc. (ISR)
IsoRay (NYSE: ISR) is a biopharmaceutical company that provides innovative solutions for the treatment and diagnosis of various diseases using advanced medical isotopes. The company, through its subsidiary IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. For more information, visit the company's website at www.isoray.com.
Ituran Location & Control Ltd. (ITRN)
Ituran Location & Control (NASDAQ: ITRN) is a technology company that provides location-based services, consisting predominantly of stolen vehicle recovery and tracking services. The company also offers wireless communications products used in connection with its location-based services mobile asset location, stolen vehicle recovery, management & control services for vehicles, cargo and personal security. Ituran has approximately 1,500 employees worldwide, provides its location based services and has a market leading position in Israel, Brazil, Argentina and the United States. For more information, visit the company's website, at www.ituran.com.
Juniper Pharmaceuticals, Inc. (JNP)
Juniper Pharmaceuticals (NASDAQ: JNP) is an innovative pharmaceutical company that develops therapeutics meant to address unmet medical needs in women's health. The company's pipeline leverages the 505(b)(2) regulatory pathway with new formulations of existing pharmaceuticals. One of Juniper's past successes includes Crinone® 8% (progesterone gel), which is commercially available in the United States and over 90 countries around the world. The company is currently developing several product candidates using its segmented intravaginal ring (IVR) technology. For more information, visit the company's website at www.juniperpharma.com.
Kadmon Corporation, LLC (KDMN)
Kadmon (OTC: KDMN) is a fully integrated biopharmaceutical company engaged in the development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The company is currently developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. Kadmon Pharmaceuticals, the company's subsidiary, distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus (HCV) infection. For more information, visit the company's website at www.kadmon.com.
Kamada Ltd. (KMDA)
Kamada (NASDAQ: KMDA) is a biopharmaceutical company focused on plasma-derived protein therapeutics for orphan indications. The company has a commercial product portfolio and a robust late-stage product pipeline. By using its patented platform and proven experience in the field of purifying proteins from human plasma, the company produces Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived proteins. AAT has newly discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. Kamada's flagship product is Glassia®, the first and only liquid intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. For more information, visit the company's website at www.kamada.com.
Karyopharm Therapeutics, Inc. (KPTI)
Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage pharmaceutical company focused on the development of novel first-in-class drugs directed against cancer and other major diseases. The company has discovered the small molecule Selective Inhibitor of Nuclear Export, or SINE™, that represent a new class of drug candidates with an innovative mechanism of action that can treat a variety of diseases in areas of unmet medical need. Its flagship drug candidate, Selinexor (KPT-330), is an XPO1 inhibitor being evaluated in multiple late-stage clinical trials in patients with relapsed hematological and solid tumor malignancies. For more information, visit the company's website at www.karyopharm.com.
Kiadis Pharma (KIADF)
Kiadis Pharma (OTC: KIADF) is a clinical-stage biopharmaceutical company that researches and develops cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company's phase 2 clinical innovative products have the potential to address the current risks and limitations connected with allogeneic hematopoietic stem cell transplantation (HSCT) and make HSCT a first-choice treatment for blood cancers and inherited blood disorders. For more information, visit the company's website at www.kiadis.com.
Kitov Pharmaceuticals Holdings Ltd. (KTOV)
Kitov Pharmaceuticals Holdings (NASDAQ: KTOV) is a late-stage drug development biopharmaceutical company that focuses on treating osteoarthritis and hypertension diseases. The company's current product pipeline features two combination drugs intended to treat osteoarthritis (OA) pain and hypertension (HTN) simultaneously. Kitov's two patent-pending products, KIT-301 and KIT-302, are combination drugs. In December 2015, KIT-302 successfully achieved the primary efficacy endpoint for its phase 3 clinical trial. For more information, visit the company's website at www.kitovpharma.com.
Ligand Pharmaceuticals, Inc. (LGND)
Ligand Pharmaceuticals (NASDAQ: LGND) is a California-based biopharmaceutical company that develops programs through a portfolio of assorted strategies and properties in the pharmaceutical industry. The company's platform technology is Captisol, a chemically modified clathrate compound of the cyclodextrin class designed to improve solubility, stability, bioavailability and dosing of active pharmaceutical ingredients. The technology has enabled seven United States Food and Drug Administration-approved products, including Kyprolis and Noxafil-IV, and is being developed in several clinical-stage partner programs. For more information, visit the company's website at www.ligand.com.
Limelight Networks, Inc. (LLNW)
Limelight Networks (NASDAQ: LLNW) is a premier content delivery network (CDN) service provider. The company's leading technologies enable organizations to deliver faster websites, more responsive applications, the highest quality video, and consistent game and software downloads to any device. It enables companies to do business online with greater speed, reliability and security. Limelight's network architecture can uniquely support both small files, and the large files that comprise most content today such as video, software and games. For more information, visit the company's website at www.limelight.com.
Lionbridge Technologies, Inc. (LIOX)
Lionbridge Technologies (NASDAQ: LIOX) is a cloud company that enables more than 800 world-leading brands to increase international market share, speed adoption of products, and effectively engage their customers in local markets worldwide. Using its innovative cloud technology platforms and a global crowd of more than 100,000 professional cloud workers, the company provides translation, online marketing, global content management and application testing solutions that ensure global brand consistency, local relevancy and technical usability across all touch points of the customer lifecycle. For more information, visit the company's website at www.lionbridge.com.
Liquidmetal Technologies, Inc. (LQMT)
Liquidmetal Technologies (OTCQB: LQMT) is dedicated to researching and developing amorphous metals. Its patented alloys and processes are at the basis of high performance materials in a broad range of medical, military, consumer, industrial and sporting goods products. Discovered by researchers at the California Institute of Technology, Liquidmetal alloys' unique atomic structure enables applications to achieve performance and accuracy levels that have not been possible before. For more information, visit the company's website at www.liquidmetal.com.
MabVax Therapeutics Holdings, Inc. (MBVX)
MabVax Therapeutics Holdings (OTC: MBVX) is a clinical-stage biotechnology corporation that develops vaccine and antibody-based products and vaccines to address various stage treatments for cancer. The company has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients. It has the exclusive license to the therapeutic vaccines from Memorial Sloan Kettering Cancer Center. MabVax has two cancer vaccines targeting recurrent sarcoma and ovarian cancer in proof-of-concept phase 2 multicenter clinical trials. For more information, visit the company's website at www.mabvax.com.
MAG Silver Corp. (MVG)
MAG Silver Corp. (NYSE: MAG) is a silver exploration company focused on advancing and exploring high-grade district scale silver projects located within the Fresnillo Silver Trend in Mexico. The company aims to become one of the premier companies in the silver mining industry. Currently, it is developing the underground decline toward the high grade Valdecañas and Juanicipio silver veins in Zacatecas State, all within the joint venture between MAG Silver (44%) and Fresnillo PLC (56%). For more information, visit the company's website at www.magsilver.com.
MagneGas Corp. (MNGA)
MagneGas (NASDAQ: MNGA) is a technology company that owns a patented process capable of converting various renewable and waste liquids into hydrogen-based fuels. These fuels can be used as a replacement to natural gas or for metal cutting. The MagneGas® fuel production systems can be set-up locally using various types of feed stock. MagneGas also sells equipment for the sterilization of bio-contaminated liquid waste for various industrial and agricultural markets. For more information, visit the company's website at www.magnegas.com.
MannKind Corp. (MNKD)
MannKind (NASDAQ: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic solutions for various medical unmet needs on the market. The company's flagship product is AFREZZA®, approved by the FDA in 2014, a rapid-acting insulin treatment for the glycemic control in diabetes patients. The product can be administered using a specially designed inhaler, dissolves rapidly upon inhalation to the deep lung, and delivers insulin quickly to the bloodstream. It utilizes the company's proprietary Technosphere® formulation technology, which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded. For more information, visit the company's website at www.mannkindcorp.com.
Marrone Bio Innovations, Inc. (MBII)
Marrone Bio Innovations (NASDAQ: MBII) aims to lead the movement to a more sustainable world through the discovery, development and marketing of biological products for pest management and plant health. The company has four products for agriculture on the market (Regalia®, Grandevo®, Venerate® and Majestene®); distributes Bio-tam 2.0® for Isagro USA in the Western U.S.; and also markets Zequanox® for invasive mussels for water markets. For more information, visit the company's website at www.marronebio.com.
Mast Therapeutics, Inc. (MSTX)
Mast Therapeutics (NYSE: MSTX) is a leading, California-based biopharmaceutical company currently developing two clinical-stage investigational new drugs for serious or life-threatening diseases and conditions. The company's main clinical candidate, Vepoloxamer, is in phase 3 clinical development for the treatment of vaso-occlusive crisis in patients with sickle cell disease, as well as is in phase 2 for the treatment of heart failure. AIR001, the company's second product candidate, is in phase 2 clinical development for the treatment of patients with heart failure with preserved ejection fraction (HFpEF). For more information, visit the company's website at www.masttherapeutics.com.
Mateon Therapeutics, Inc. (MATN)
Mateon Therapeutics (NASDAQ: MATN), formerly Oxigene, is a biopharmaceutical company striving to develop solutions and leverage the full potential of vascular targeted therapy (VTT) in orphan oncology indications. VTTs include vascular disrupting agents (VDAs), such as the investigational drugs that the company is developing, and anti-angiogenic agents (AAs), a number of which are FDA-approved and widely used in cancer treatment. These two approaches (VDAs and AAs) have distinct yet complementary mechanisms of action. The company's main aim is to significantly improve cancer therapy by combining these two complementary approaches. For more information, visit the company's website at www.mateon.com.
Matinas BioPharma Holdings, Inc. (MTNB)
Matinas BioPharma Holdings (OTC: MTNB) is a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections. The company's lead anti-infective product candidates, MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulations. For more information, visit the company's website at www.matinasbiopharma.com.
MaxPoint Interactive, Inc. (MXPT)
MaxPoint Interactive (NASDAQ: MXPT) is a global marketing technology company that generates hyperlocal intelligence to optimize brand and retail performance. The company provides a platform for brands to connect the digital world with the physical world through hyperlocal execution, measurement and consumer insights. Its proprietary Digital Zip® technology and the MaxPoint Intelligence Platform™ predict the most likely buyers of a specific product at a particular retail location and then execute cross-channel digital marketing programs to reach these buyers. For more information, visit the company's website at www.maxpoint.com.
McEwen Mining, Inc. (MUX)
McEwen Mining (NYSE: MUX) is a gold and silver producer focused in the Americas and Europe. The company's principal assets consist of the San José Mine in Santa Cruz, Argentina (49% interest), the El Gallo Mine and El Gallo Silver project in Sinaloa, Mexico, the Gold Bar project in Nevada, USA, and the Los Azules copper project in San Juan, Argentina. For more information, visit the company's website at www.mcewenmining.com.
MDxHealth SA (MXDHF)
MDxHealth SA (OTC: MXDHF) is a multinational healthcare provider that focuses on delivering actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's proprietary tests are based on gene methylation (epigenetic) and other molecular technologies and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information, visit the company's website at www.mdxhealth.com.
Medgenics, Inc. (MDGN)
Medgenics (NYSE: MDGN) is a research company dedicated to unlocking the potential of genomic medicine. The company's uses TARGT™ (Transduced Autologous Restorative Gene Therapy), a proprietary gene therapy platform. Its internal research and development and ongoing sponsored research with a well-respected pediatric academic medical center give Medgenics the ability to focus on the underlying genetic pathway of pediatric diseases with the goal of finding therapeutic solutions for subpopulations of both children and adults living with rare and other difficult-to-treat diseases. For more information, visit the company's website at www.medgenics.com.
Mesoblast Ltd. (MESO)
Mesoblast (NASDAQ: MESO) is a global leader in the development of innovative cell-based therapies. The company uses its patented technology platform based on specialized cells known as mesenchymal lineage adult stem cells to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases such as cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. For more information, visit the company's website at www.mesoblast.com.
Microvision, Inc. (MVIS)
Microvision (NASDAQ: MVIS) is a global leader in the development of intellectual property. The company's IP portfolio has been recognized by IEEE, the Patent Board, as a Top 50 IP portfolio among global industrial companies. Microvision's patented product is the PicoP® scanning technology, an ultra-miniature laser projection and imaging solution based on the laser beam scanning methodology the company pioneered. For more information, visit the company's website at www.microvision.com.
Midatech Pharma (MTP)
Midatech Pharma (NASDAQ: MTP) is a nanomedicine company focused on advancing a pipeline of novel clinical and pre-clinical product candidates based on its proprietary drug conjugate and sustained release delivery platforms with a clear focus on the key therapeutic areas of diabetes, cancer and neuroscience/ophthalmology. Midatech's strategy is to develop its products in-house in rare cancers and with partners in other indications, and to accelerate growth of its business through the strategic acquisition of complementary products and technologies. For more information, visit the company's website at www.midatechgroup.com.
Midwest Energy Emissions Corp. (MEEC)
Midwest Energy Emissions (OTC: MEEC) delivers patented, cost-effective mercury capture solutions to coal-fired power plants and other large industrial coal-burning units. The company's proprietary technology delivers a flexible, tunable solution that allows the global coal-power industry to comply with new, highly restrictive regulations on mercury air emissions. It offers the least disruption to current equipment and on-going plant operations, while preserving the ability to re-cycle fly-ash for beneficial use. For more information, visit the company's website at www.midwestemissions.com.
Mirna Therapeutics, Inc. (MIRN)
Mirna Therapeutics (NASDAQ: MIRN) is a clinical-stage biopharmaceutical company that works on the development of a broad pipeline of microRNA-based oncology therapeutics. The company's lead product candidate, MRX34, is the first microRNA mimic to enter clinical development and has demonstrated clinical proof of concept as a single agent in its ongoing phase 1 clinical trial. MRX34 was designed to deliver a mimic of the naturally occurring microRNA tumor suppressor miR-34, which is under expressed in a wide variety of cancers – liver cancer, lymphomas and leukemia. For more information, visit the company's website at www.mirnarx.com.
Mogo Finance Technology, Inc. (MFTGF)
Mogo Finance Technology (OTC: MFTGF) is a Canadian financial technology company that offers a more convenient and engaging digital banking experience with its free Mogo®Account. The company is quickly becoming the new face of banking as it grows its member base faster than any of the top six banks in Canada. For more information, visit the company's website at www.mogo.ca.
Moleculin Biotech, Inc. (MBRX)
Moleculin Biotech (NASDAQ: MBRX) is a preclinical and clinical stage pharma company that focuses on developing innovative cancer drug treatments. Some of these are based on the discoveries made at M.D. Anderson Cancer Center, the world's largest cancer research facility. Moleculin's lead product candidate is Annamycin, an anthracycline currently in phase 2 clinical stage, designed for the treatment of AML (acute myeloid leukemia). Moleculin is also developing other drug candidates currently in pre-clinical stage: two small molecule portfolios that target the modulation of tumor cell signaling mechanisms and the metabolism of tumors. For more information, visit the company's website at www.moleculin.com.
Learn How to Become a Client-Partner
We have a full suite of powerful communications tools as well as an expansive network of more than 5,000 key distribution points. Interested in putting it all to work for you? Leveraging a professional team of journalists and writers, NNW can introduce you to a wide audience of investors, consumers, journalists and the general public.
If would like to work with us, visit our Become a Client-Partner page.